Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ramalingam

Showing results (181-190 of 502) with videos related to

Pageof 51
Sort By:
Cancer Biology & Therapy|November 5, 2008
Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacyXuerong Wang, Natalyn Hawk, Ping Yue, et al.
Lung Cancer (Amsterdam, Netherlands)|December 13, 2023
Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectivesTerufumi Kato, Ignacio Casarini, Manuel Cobo, et al.
The Oncologist|February 22, 2017
Using Metaphors to Explain Molecular Testing to Cancer PatientsAna P M Pinheiro, Rachel H Pocock, Margie D Dixon, et al.
Lung Cancer (Amsterdam, Netherlands)|August 10, 2018
Common cancer-driver mutations and their association with abnormally methylated genes in lung adenocarcinoma from never-smokersMathewos Tessema, Michael R Rossi, Maria A Picchi, et al.
Lung Cancer (Amsterdam, Netherlands)|May 2, 2012
Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysisMadhusmita Behera, Taofeek K Owonikoko, Zhengjia Chen, et al.
Cancer|March 6, 2015
Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508)Nasser H Hanna, Suzanne E Dahlberg, Jill M Kolesar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2007
Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results databaseTaofeek K Owonikoko, Camille C Ragin, Chandra P Belani, et al.
Chest|December 17, 2017
Impact of a Non-small Cell Lung Cancer Educational Program for Interdisciplinary TeamsSeptimiu Murgu, Robb Rabito, Greg Lasko, et al.
JTO Clinical and Research Reports|September 30, 2021
Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504)Saad A Khan, Zhuoxin Sun, Suzanne Dahlberg, et al.
Cancer Letters|August 31, 2025
Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancerZhen Chen, Karin A Vallega, Dongsheng Wang, et al.
Pageof 51

Showing results (181-190 of 502) with videos related to

Sort By:
Pageof 51
Cancer Biology & Therapy|November 5, 2008
Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacyXuerong Wang, Natalyn Hawk, Ping Yue, et al.
Lung Cancer (Amsterdam, Netherlands)|December 13, 2023
Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectivesTerufumi Kato, Ignacio Casarini, Manuel Cobo, et al.
The Oncologist|February 22, 2017
Using Metaphors to Explain Molecular Testing to Cancer PatientsAna P M Pinheiro, Rachel H Pocock, Margie D Dixon, et al.
Lung Cancer (Amsterdam, Netherlands)|August 10, 2018
Common cancer-driver mutations and their association with abnormally methylated genes in lung adenocarcinoma from never-smokersMathewos Tessema, Michael R Rossi, Maria A Picchi, et al.
Lung Cancer (Amsterdam, Netherlands)|May 2, 2012
Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysisMadhusmita Behera, Taofeek K Owonikoko, Zhengjia Chen, et al.
Cancer|March 6, 2015
Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508)Nasser H Hanna, Suzanne E Dahlberg, Jill M Kolesar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2007
Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results databaseTaofeek K Owonikoko, Camille C Ragin, Chandra P Belani, et al.
Chest|December 17, 2017
Impact of a Non-small Cell Lung Cancer Educational Program for Interdisciplinary TeamsSeptimiu Murgu, Robb Rabito, Greg Lasko, et al.
JTO Clinical and Research Reports|September 30, 2021
Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504)Saad A Khan, Zhuoxin Sun, Suzanne Dahlberg, et al.
Cancer Letters|August 31, 2025
Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancerZhen Chen, Karin A Vallega, Dongsheng Wang, et al.
Pageof 51